Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Northwestern University
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06247540CT.gov Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | Withdrawn | — | — | — |
NCT05672173CT.gov Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation | — | Active Not Recruiting | — | — | — |
NCT04781855CT.gov Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation | — | Withdrawn | — | — | — |
NCT03892044CT.gov Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma | — | Completed | — | — | — |
NCT03884998CT.gov Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT02420912CT.gov Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Richter Transformation
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivolumab (this asset) | Northwestern University | P2 | B · 60 |
| Obinutuzumab | Christine Ryan | P2 | BB |
| Ibrutinib | City of Hope Medical Center | P2 | BB |
| Venetoclax | Northwestern University | P2 | BB |
| Adriamycin | SWOG Cancer Research Network | P3 | BB |
| Prednisone | SWOG Cancer Research Network | P3 | BB |
| Pirtobrutinib | SWOG Cancer Research Network | P3 | BB |
| Cyclophosphamide | SWOG Cancer Research Network | P3 | BB |
| Rituximab | SWOG Cancer Research Network | P3 | BB |
+42 more in the Richter Transformation cohort
Other indications for Nivolumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BBB · 72 |
| Metastatic Melanoma | — | P4 | BB · 70 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivolumab in Richter Transformation. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nivolumab-richter-transformation
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →